Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus QVAR 40.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus QVAR 40.
AZMACORT vs QVAR 40
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Beclomethasone dipropionate is a corticosteroid with potent anti-inflammatory activity. It binds to glucocorticoid receptors, leading to modulation of gene expression and inhibition of inflammatory mediators such as cytokines, leukotrienes, and prostaglandins. It reduces airway hyperresponsiveness and inflammation.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
40-160 mcg inhaled twice daily for asthma maintenance; maximum 320 mcg/day.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2.9 hours in adults after inhalation, reflecting rapid clearance from plasma.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Primarily hepatic metabolism via CYP3A4, with inactive metabolites excreted in feces (approximately 60-70%) and urine (30-40%). Less than 10% excreted unchanged.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid